Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
Purpose of Review Chronic kidney disease and end-stage kidney disease (ESKD) are well-
established risk factors for cardiovascular disease (CVD), the leading cause of mortality in …
established risk factors for cardiovascular disease (CVD), the leading cause of mortality in …
[HTML][HTML] Unveiling the enigma of acute kidney disease: predicting prognosis, exploring interventions, and embracing a multidisciplinary approach
SY Pan, TTM Huang, ZH Jiang, LC Lin… - Kidney Research and …, 2024 - ncbi.nlm.nih.gov
Acute kidney disease (AKD) is a critical transitional period between acute kidney injury and
chronic kidney disease. The incidence of AKD following acute kidney injury is approximately …
chronic kidney disease. The incidence of AKD following acute kidney injury is approximately …
[PDF][PDF] Expert opinion on the use of SGLT2 inhibitors and its combination with a special focus on dapagliflozin in the management of type 2 diabetes in Indian settings
S Manjula - International Journal of Endocrinology, 2024 - endocrinologyjournal.net
Objective: The current survey-based study aims to gather expert opinion regarding the
prescription practice of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and its …
prescription practice of sodium-glucose cotransporter-2 inhibitors (SGLT2i) and its …
Proteomic analysis and sex-specific changes in chronically ischemic swine myocardium treated with sodium-glucose cotransporter-2 inhibitor canagliflozin
DD Harris, SA Sabe, M Broadwin, C Stone… - Journal of the …, 2023 - journals.lww.com
Background: Although sodium-glucose cotransporter-2 (SGLT-2) inhibitors have been
shown to improve cardiovascular outcomes in general, little is presently known about any …
shown to improve cardiovascular outcomes in general, little is presently known about any …
Cardiovascular outcomes between dapagliflozin versus empagliflozin in patients with diabetes mellitus
JH Kim, YC Yoon, YH Kim, JI Park, KU Choi… - Clinical …, 2024 - Wiley Online Library
Background Sodium‐glucose co‐transporter 2 (SGLT2) inhibitors have been demonstrated
to decrease cardiovascular adverse events. However, there is little real‐world clinical …
to decrease cardiovascular adverse events. However, there is little real‐world clinical …
NESS Commentary re Sellke 2023-1430
AB Ingason, MC Norotsky - Journal of the American College of …, 2023 - journals.lww.com
Sodium glucose transporter 2 (SGLT2) inhibitors are a class of antihyperglycemic
medications that prevent reabsorption of glucose in the proximal convoluted tubules. They …
medications that prevent reabsorption of glucose in the proximal convoluted tubules. They …
Exploring the Outcomes of SGLT2 Inhibitors in Diabetics Patients at Dialysis Commencement: A Health Global Federated Network Analysis
CA Wang, LC Lin, JY Chen, WJ Wang… - Li-Chun and Chen, Jui-Yi … - papers.ssrn.com
Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a class of
antihyperglycemic medications with proven cardiovascular and kidney benefits. However …
antihyperglycemic medications with proven cardiovascular and kidney benefits. However …